Five Prime Therapeutics Stock Analysis (NASDAQ:FPRX)

Add to My Stocks
$43.65 $0.15 (0.34%) FPRX stock closing price Jan 23, 2017 (Closing)
Watch Robo Advisor Video of FPRX Stock Analysis
Five Prime Therapeutics
Updated on : Jan 23, 2017
previous close
FPRX 43.7 (0%)
S&P 500 2265.2 (0%)
Closing Price On: Jan 23, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
69%
Sector Average:
-1.3%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Compared to the industry
Cash Flow
Operating cash flow:
-$15.7M
Net Income:
-$19.4M
PROS      CONS
Operating Margins
ROE
PE Valuation
PS Valuation
FCF Margin
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
FPRX PS :
3.1
Industry PS :
4.4
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
68.9%
Free Cash Flow Margin:
-238.5%
Double Tap To Exit Full Screen
0:00
/

Five Prime Therapeutics Analysis Video

116 5 2

View Five Prime Therapeutics stock analysis video. This is our FPRX analyst opinion covering the buy and sell arguments for FPRX stock.

Five Prime Therapeutics Inc Stock Rating (3.3/5)

Our Five Prime Therapeutics stock opinion is based on fundamentals of the company. This Five Prime Therapeutics stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy FPRX stock?

  • Five Prime Therapeutics's average operating margin of 69% was exceptional.
  • FPRX stock is trading at an earnings multiple of 4.9 which is better than the industry average of 21.8.
  • The lower PS ratio 3.1 for FPRX stock versus Medical-Biomed-Genetics industry average of 4.4 is a positive for the company.
  • Five Prime Therapeutics has a good Return On Equity (ROE) of 68.9%.

Should you sell FPRX stock?

  • Five Prime Therapeutics has a negative FCF (Free Cash Flow) margin of -238.5%.

Comments on this video and Five Prime Therapeutics stock